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A uniﬁed lead-oriented synthesis of over ﬁfty
molecular scaﬀolds†
Richard G. Doveston,a Paolo Tosatti,a Mark Dow,a Daniel J. Foley,a Ho Yin Li,a
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Controlling the properties of lead molecules is critical in drug discovery, but sourcing large numbers of
lead-like compounds for screening collections is a major challenge. A uniﬁed synthetic approach is
described that enabled the synthesis of 52 diverse lead-like molecular scaﬀolds from a minimal set of 13
precursors. The divergent approach exploited a suite of robust, functional group-tolerant transformations.
Crucially, after derivatisation, these scaﬀolds would target signiﬁcant lead-like chemical space, and comp-
lement commercially-available compounds.
Introduction
Control of molecular properties is crucial in drug discovery,
and experience has provided sets of guidelines that can steer
medicinal chemists towards drug-like chemical space. For
example, Lipinski’s rule-of-five was formulated to predict oral
bioavailability,1,2 and, in the case of central nervous system
(CNS) drug discovery, more restricted guidelines can assist the
design of compounds able to penetrate the blood-brain
barrier.3,4 Conversely, relaxation of molecular property guide-
lines is generally required to enable the discovery of small
molecule inhibitors of protein–protein interactions.‡5,6 The
molecular properties of clinical candidates strongly influence
the probability of successful progression towards marketed
drugs.7–11 Key parameters that correlate strongly with success
in drug discovery include molecular weight,7,8 lipophilicity8–10
and the fraction of sp3-hybridised carbons,11 some of which
have been captured within a single metric that estimates drug-
likeness.12
The identification of high quality lead compounds is a key
challenge in early stage drug discovery. Lead optimisation
tends to increase both molecular weight and lipophilicity, as
well as molecular complexity.13–16 It is advisable, therefore, to
control the properties of lead compounds to facilitate the
emergence of clinical candidates with desirable drug-like
characteristics. As a result, approaches have been developed to
define chemical space that is populated by molecules with
good lead-like properties typically by considering factors such
as lipophilicity (e.g.17 −1 < clog P < 3), molecular size (e.g.17 14
≤ heavy atoms ≤ 26) and removal of undesirable sub-
structures.17
High-throughput screening provides a significant source of
starting points for drug discovery.14,18 Control of the molecular
properties of screening compounds can both aid subsequent
development into high-quality lead molecules, and increase
the eﬃciency of the exploration of chemical space.19 However,
sourcing large numbers of diverse compounds with appropri-
ate molecular properties has been identified as a major chal-
lenge.17 In a recent analysis, just 2.6% of 4.9 M commercially-
available compounds were found to survive filtering by mole-
cular weight (200 ≤ MR ≤ 360), lipophilicity (−1 < clog P < 3)
and various structural features known to be undesirable in
drug candidates.17 In addition, the ability of emerging syn-
thetic methods to deliver lead-like compounds has been very
poorly demonstrated17 despite significant development of
diversity-oriented synthetic approaches.20–22 The problem is in
fact exacerbated when diversity is also considered because che-
mists have historically explored chemical space unsystemati-
cally and in an uneven manner;23 indeed, metrics have been
developed to capture the scaﬀold diversity of screening collec-
tions.24 The realisation of lead-oriented synthesis has recently
been framed as a major academic and practical challenge17
which has prompted the development of approaches25,26 to
the synthesis of specific classes of lead-like molecules.27–30
We have established a programme focussed on developing
general synthetic approaches to diverse and novel lead-like
molecular scaﬀolds i.e. scaﬀolds with the potential, following
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c4ob02287d
‡ It has been suggested that new approaches may be required to translate such
molecules into marketed drugs (see ref. 5).
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diversification, to yield large numbers of compounds with
lead-like molecular properties. In this case, our approach to
exemplifying the strategy exploited a single connective reaction
in combination with just six distinct cyclisations (Scheme 1).
Ir-catalysed amination31–36 was selected as the connective reac-
tion because we had previously retooled it for compatibility
with polar, sp3-rich, functionalised substrates35 that would
have particular value for targeting lead-like chemical space.
Thus, reaction between allylic carbonates 1 and amines 2
would provide cyclisation precursors 3. Importantly, the build-
ing blocks would be armed with functional groups to enable
subsequent cyclisation – either once (e.g. → 4 or 5) or twice
(e.g. → 6) – to yield product scaﬀolds. In addition, more
complex scaﬀolds might be accessible by exploitation of a
third building block (e.g. → 7–9). Remaining functionality
would then be available for late-stage scaﬀold decoration. Our
aim was to prepare, in a synthetically concise and eﬃcient
manner, a wide range of diverse and novel molecular scaﬀolds
that, following decoration, would target broad regions of lead-
like chemical space and thus demonstrate the potential of the
strategy to underpin early-stage drug discovery.
Results
Synthesis of cyclisation precursors
We selected a number of densely functionalised cyclisation
precursors that could facilitate the synthesis of a wide range of
novel and diverse lead-like molecular scaﬀolds. Thirteen cycli-
sation precursors were prepared from combinations of an
amine (10 alternatives) and an allylic carbonate (2 alternatives)
building block in good to excellent yield, and with high
enantio- or diastereoselectivity (Scheme 2). The building
blocks were either commercially available or were prepared on
a multi-gram scale using well established methods. In most
cases, our previously reported protocol, which enables eﬃcient
coupling of unprotected polar amines, was used.35 Thus, the
active catalyst was generated from 2 mol% [Ir(dbcot)Cl]2, 4 mol
% chiral ligand [either (R,R,aR)- or (S,S,aS)-10] and 4 mol%
BuNH2 in DMSO at 55 °C before the building blocks were
Scheme 2 Synthesis of cyclisation precursors by Ir-catalysed reaction
between amine and allylic carbonate building blocks. a(S,S,aS)-10 was
used. bPrNH2 and THF were used.
cThe amine HCl salt and 1.3 eq. K3PO4
were used. dbcot = dibenzo[a,e]cyclooctatetraene; TBDPS = tert-butyl-
diphenylsilyl; Ns = 2-nitrobenzenesulfonyl.
Scheme 1 Overview of the uniﬁed approach to the synthesis of lead-
like molecular scaﬀolds. Reaction between an allylic carbonate (1; blue)
and an amine (2; green) would yield a cyclisation precursor 3. Reactive
sites that may enable cyclisation or functionalisation (ﬁlled circles), third
building blocks (red) and new bonds (bold) are indicated.
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added. In some cases, the use of DMSO was not required, and
THF was used as the reaction solvent.31
Synthesis of lead-like molecular scaﬀolds
A toolkit of six cyclisation reactions was then exploited to
convert the thirteen cyclisation precursors (11–23) into lead-
like molecular scaﬀolds. Selected syntheses of scaﬀolds are
presented in Schemes 3 and 4 (see ESI† for full details). In
order to maximise the number of scaﬀolds prepared, a diver-
gent synthetic approach was adopted that exploited each of the
six methods in the first cyclisation step (Methods A–F;
Scheme 3).
For example, Pd-catalysed aminoarylation (Method A),37,38
if necessary after protection of the secondary amine, enabled
conversion of the cyclisation precursors 11, 14 and 15 into the
pyrrolidines 24–28. In each case, the reaction proceeded
Scheme 3 Selected syntheses of lead-like scaﬀolds prepared using a single cyclisation step (indicated by colour: A, yellow, Pd-catalysed aminoaryl-
ation; B, purple, iodocyclisation/displacement; C, pink, reaction with CDI; D, green, reaction with α-halo acetyl halide; E, light blue, ring-closing
metathesis; F, peach, lactamisation). Typical methods (see ESI† for full details): A: Aryl bromide (1.2 eq.), 5 mol% Pd(OAc)2, 10 mol% DPE-Phos,
Cs2CO3 (2.5 eq.), 1,4-dioxane, 105 °C; B: (i) NsCl (1.2 eq.), NEt3 (2.0 eq.), DMAP (0.1 eq.), rt, then TBAF (1.2 eq.), AcOH (1.2 eq.), THF, rt; (ii) NIS (1.5
eq.), MeCN, 65 °C; (iii) ArSH (1.5 eq.), DBU (2.5 eq.), MeCN, rt; (iv) mCPBA (4.0 eq.), CH2Cl2, rt; (v) PhSH (1.2 eq.), DBU (1.5 eq.), MeCN, rt; C1: CH2Cl2–
TFA, 0 °C → rt, then CDI (1.5 eq.), DBU (4.0 eq.), THF, 50 °C; C2: CDI (4.5 eq.), DMF, 110 °C; C3: CDI (1.5 eq.), DBU (2.5 eq.), THF, 50 °C; D1: Chloro-
acetyl chloride (1.5 eq.), NEt3 (5.0 eq.), CH2Cl2, 0 °C → rt, then NaH (2.0 eq.), NaI (1.0 eq.), THF, rt; D2: (i) TMSCl (1.1 eq.), NEt3 (3.0 eq.),CH2Cl2, 0 °C
→ rt, then bromoacetyl bromide (1.5 eq.), then 20% AcOH (aq.), rt; (ii) 35% NaOH (aq.) (5.0 eq.), Bu4NSO4 (0.5 eq.), CH2Cl2, 0 °C → rt; E1: 5 mol%
Grubbs II, CH2Cl2, reﬂux; F1: CH2Cl2–TFA, 0 °C → rt, then K2CO3 (6.0 eq.), CH2Cl2, H2O, rt; F2: CH2Cl2–TFA, 0 °C → rt, then NaOtBu (2.0 eq.), THF,
reﬂux; TBDPS = tert-butyldiphenylsilyl; Ns = 2- or 4-nitrobenzenesulfonyl; DMAP = 4-dimethylaminopyridine; TBAF = tetra-n-butylammonium
ﬂuoride; DBU = 1,8-diazabicycloundec-7-ene; mCPBA = m-chloroperoxybenzoic acid; DPE-Phos = bis-[2-(diphenylphosphino)phenyl]ether; TFA =
triﬂuoroacetic acid; CDI = carbonyl diimidazole.
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eﬃciently and with high diastereoselectivity.§ Iodocylisation39
(Method B) enabled the cyclisation precursor 11 to be con-
verted, after protecting group manipulation, into the corres-
ponding morpholine (dr 56 : 44); subsequent treatment with
4-methyl-4H-1,2,4-triazole-3-thiol and DBU gave separable sul-
fides which were oxidised and then deprotected to give the
morpholine 29. Methods A and B both exploit a potentially
variable building block – a (het)aryl bromide or a thiol respect-
ively – and may therefore enable variation of the specific
scaﬀold prepared. The application of alternative electron-
deficient (het)aryl bromides in an initial cyclisation by ami-
noarylation was exemplified in the synthesis of nine scaﬀolds,
five of which are shown in Scheme 3.
Two cyclisation reactions (Methods C and D) exploited
simple bifunctional reagents that enabled the formation of a
range of five-, six- and seven-membered ring systems. Thus,
reaction with CDI (Methods C), if necessary after a telescoped
protecting group removal, gave either cyclic ureas (e.g. 30 and
31) or oxazolidinones (e.g. 32). Similarly, reaction with either
chloroacetyl chloride or bromoacetyl bromide, followed by
alkylation, (Methods D) enabled the synthesis of ketopipera-
zines (e.g. 33) and ketomorpholines (e.g. 34). In addition,
Scheme 4 Selected syntheses of lead-like scaﬀolds prepared using a second cyclisation step (including telescoped procedures; shown in blue).
Methods are consistent with those in Scheme 3 (indicated by colour: A, yellow, Pd-catalysed aminoarylation; B, purple, iodocyclisation/displace-
ment; C, pink, reaction with CDI; D, green, reaction with α-halo acetyl halide; E, light blue, ring-closing metathesis; F, peach, lactamisation).
Additional methods (see ESI† for full details): D3/E2: (i) Bromoacetyl bromide (1.1 eq.), DIPEA (1.2 eq.), CH2Cl2, 0 °C → rt; (ii) 5 mol% Grubbs II,
CH2Cl2, 45 °C; (iii) NaH (2.0 eq.), THF, rt; F3: 10% Pd/C (20 mol% Pd), ethylenediamine (1.0 eq.), MeOH, rt, then Cs2CO3 (10.0 eq.), DMF, 110 °C;
TBDPS = tert-butyldiphenylsilyl.
§Substrates bearing a remote o-nitrosulfonyl-protected amine did not undergo
clean aminoarylation (see ESI†).
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2-keto-1,4-diazepane formation was also possible from the
homologous substrates, although generally telescoped with a
second cyclisation step (see below). Ring-closing metathesis
(Methods E) was often used as a single cyclisation to form tet-
rahydropyridines (e.g. 35) or dihydropyrroles (e.g. 36) but could
also be telescoped with a second cyclisation step (see below).
Finally, lactamisation (Methods F) enabled the formation of
either six- (e.g. 37) or seven- (e.g. 38) membered lactams.
In many cases, a second cyclisation step was possible using
one of the complementary cyclisation reactions (Scheme 4).
The robustness of Pd-catalysed aminoarylation (Method A)
enabled the formation of pyrrolidines from a wide range of
substrates. For example, the substrates 31–34 were converted
into the pyrrolidines 39–43 with consistently high diastereo-
selectivity. Again, the ability to vary the scaﬀold prepared
through careful choice of (het)aryl bromide was widely demon-
strated. Method C also had utility as a second cyclisation: Boc
deprotection of 29, followed by reaction with CDI, enabled the
synthesis of the bicyclic scaﬀold 44.
As already noted, telescoped procedures incorporating a
second cyclisation step were often used to great eﬀect
(Scheme 4; structures shown in blue). For example, ring-
closing metathesis (Methods E) followed by urea formation
(Methods C) enabled the synthesis of bicyclic compounds 45
and 46 directly from acyclic cyclisation precursors (19 and 17).
Alternatively, telescoped diketopiperazine or 2-keto-1,4-diaze-
pane formation (Methods D) and ring-closing metathesis pro-
cedures enabled the facile synthesis of compounds 47–49.
Lactamisation (Method F) had particular value for sub-
strates prepared by aminoarylation with 2-methoxycarbonyl-
phenyl bromide in the first cyclisation. For example,
deprotection of 24, 26 and 27 triggered cyclisation to yield
either six- (e.g. 50, 52 or 53) or seven- (e.g. 51) membered
lactams. In the case of pyrrolidine 26, the selective formation
of two distinct scaﬀolds (50 and 51) was possible using ortho-
gonal deprotection reactions.
Discussion
To assess the value of the 52 scaﬀolds prepared, a virtual
library of functionalised compounds was enumerated (see ESI†
for full details). The deprotected scaﬀolds were combined with
59 exemplar medicinal chemistry capping groups. For most
scaﬀolds, up to two capping groups were used. However, for
scaﬀolds whose synthesis had already involved a variable reac-
tant (e.g. those prepared by aminoarylation), only one capping
group was exploited. The resulting virtual library comprised
19 530 likely synthetically-accessible small molecules. To
confirm the validity of this analysis, we demonstrated experi-
mentally that scaﬀold decoration was possible to yield exem-
plar lead-like compounds from the virtual library (see ESI†).
First, the lead-likeness of the members of the virtual library
was assessed (Fig. 1, Panel A). Compounds were successively
filtered by molecular size (14 ≤ number of heavy atoms ≤ 26),
lipophilicity (−1 ≤ Alog P ≤ 3) and undesirable structural
features (see ESI† for specific structural filters). About 59% of
the compounds in the virtual library had lead-like molecular
Fig. 1 Analysis of the molecular properties of a virtual library of 19 530
compounds derived from the 52 molecular scaﬀolds and 1% of the ZINC
database (90 911 randomly-selected compounds).†† Panel A: Distri-
bution of the molecular properties of the virtual library. 59% of the com-
pounds (green) survive successive ﬁltering by molecular size (14 ≤
number of heavy atoms ≤ 26; failures shown in red) and lipophilicity (−1
≤ Alog P ≤ 3; failures shown in orange) and various structural ﬁlters;
0.27% of the compounds (shown in black) failed the structural ﬁlters.
Panel B: Distribution of the molecular properties of the compounds
from the ZINC database. Using the same approach, 23% of the com-
pounds survive the iterative ﬁltering process, and 9% of the compounds
fail a structural ﬁlter. Panel C: Mean Fsp3 of the compounds from the
ZINC database (red) and our virtual library (overall mean, black; and
mean for the compounds based on each of the 52 scaﬀolds, green).
††The properties of these compounds are representative of the entire ZINC data-
base of ∼9 M commercially-available compounds (see ESI†).
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properties, and the majority of the outlying compounds only
narrowly failed the molecular property filters (heavy atoms: μ =
23.8, σ = 4.0; Alog P: μ = 0.3, σ = 1.3). By comparison, with
these specific filters, just 23% of ∼9 M commercially-available
compounds from the entire ZINC database40 were lead-like,
with the majority of compounds lying well outside lead-like
chemical space (heavy atoms: μ = 25.9, σ = 5.4; Alog P: μ = 1.7,
σ = 2.9) (Fig. 1, Panel B).¶41 Remarkably, we also showed that,
with this set of capping groups, each one of the 52 scaﬀolds
allowed significant regions within lead-like chemical space to
be targeted (see ESI†). Our unified synthetic approach thus
specifically targeted lead-like chemical space.
Second, we determined the fraction of sp3-hybridised
carbon atoms (Fsp3) in the virtual compounds (Fig. 1, Panel
C). It has previously been shown that Fsp3 correlates strongly
with success because compounds in the discovery phase
(mean Fsp3: 0.36) have lower Fsp3 than marketed drugs (mean
Fsp3: 0.47).11 It has thus been stated that accessing more
three-dimensional lead compounds is a desirable goal.11,17
The mean Fsp3 of the virtual compounds (0.58) compared very
favourably with that of the random sample of compounds
from the ZINC database (0.33). Thus, our synthetic approach
can yield compounds with significantly greater sp3 character
than most commercially-available compounds, thereby
expanding the range of molecular architectures available
within lead-like chemical space and oﬀering more flexibility in
lead optimisation.
Third, the novelty and diversity of the 52 scaﬀolds was
assessed. A substructure search was performed in which the
ZINC database (9 046 036 compounds) was interrogated with
each of the deprotected scaﬀolds. In 43 cases (82%), the depro-
tected scaﬀold was not found as a substructure in any com-
pound in the database. Even in the remaining 9 cases, the
deprotected compound was not known in the CAS registry. The
diversity of, and relationship between, the scaﬀolds was
assessed using an hierarchical analysis (see ESI†).42 It was
found that 42 frameworks were represented at the graph-node-
bond level, which were related hierarchically to 13 “parent”
frameworks. There is significant scaﬀold diversity at each level
of hierarchy, meaning that the scaﬀolds are not simply closely
related derivatives.
In total, 52 diverse molecular scaﬀolds were prepared from
just thirteen diﬀerent cyclisation precursors. Initially, pairs of
building blocks were combined using a single connective reac-
tion – Ir-catalysed allylic amination – before a divergent syn-
thetic approach was used to convert these cyclisation
precursors into 52 molecular scaﬀolds. This approach
exploited a toolkit of just six cyclisation reactions, and required
on average just 3.0 operationsk for the synthesis of the
scaﬀolds from the constituent building blocks. Furthermore,
the unified and modular nature of the strategy means that it
has the potential to deliver many additional scaﬀolds through
expansion of the range of building blocks used (e.g. by use of
homologated, and stereo- or regioisomerically substituted
variants).
Conclusions
Our unified synthetic approach yielded molecular scaﬀolds
that were novel, diverse and lead-like. It was shown that func-
tionalisation of the scaﬀolds would allow significant lead-like
chemical space to be targeted that complements that occupied
by commercially-available molecules. A key challenge in lead-
oriented synthesis is the identification of complementary and
robust reactions with broad functional group compatibility,
particularly convergent reactions that may be used to link
building blocks.**43 The success of our unified lead-oriented
synthetic approach was founded in the identification of a
robust convergent reaction that, together with a range of cycli-
sation reactions, could be exploited in the synthesis of a wide
range of novel, diverse and lead-like molecular scaﬀolds. An
increased armoury of such robust convergent reactions would
crucially expand the relevant chemical space accessible to drug
discovery programmes, and may help to address the grand
challenge of increasing productivity in the pharmaceutical
sector.44,45
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